The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC

被引：20
|
作者：
Heymach, J. [1 ]
Taube, J. [2 ]
Mitsudomi, T. [3 ]
Harpole, D. [4 ]
Aperghis, M. [5 ]
Trani, L. [5 ]
Powell, M. [6 ]
Dennis, P. [6 ]
Reck, M. [7 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] Kindai Univ, Fac Med, Dept Surg, Div Thorac Surg, Osakasayama, Japan
[4] Duke Univ, Dept Surg, Durham, NC USA
[5] Astrazeneca, Cambridge, England
[6] Astrazeneca, Gaithersburg, MD USA
[7] Airway Res Ctr North, Grosshansdorf, Germany
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Chemotherapy; durvalumab; NSCLC;
D O I：
10.1016/j.jtho.2019.08.1318
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.18-02
引用
收藏
页码：S625 / S626
页数：2
相关论文
共 50 条
  • [41] Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)
    Ozguroglu, M.
    Levy, B.
    Horinouchi, H.
    Yu, J.
    Grainger, E.
    Phuong, P.
    Peterson, D. A.
    Newton, M.
    Spira, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S991 - S991
  • [42] Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
    Goetze, Thorsten O.
    Reichart, Alexander
    Bankstahl, Ulli S.
    Pauligk, Claudia
    Loose, Maria
    Kraus, Thomas W.
    Elshafei, Moustafa
    Bechstein, Wolf O.
    Trojan, Joerg
    Behrend, Matthias
    Homann, Nils
    Venerito, Marino
    Bohle, Wolfram
    Varvenne, Michael
    Bolling, Claus
    Behringer, Dirk M.
    Kratz-Albers, Karsten
    Siegler, Gabriele M.
    Hozaeel, Wael
    Al-Batran, Salah-Eddin
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (06) : 4073 - 4083
  • [43] Phase 2 Trial of Neoadjuvant Camrelizumab Plus Chemotherapy or Apatinib for Resectable or Potentially Resectable NSCLC
    Jiang, G.
    Zhang, P.
    Li, Q.
    Chen, H.
    Xie, S.
    Zhang, H.
    Ruan, Z.
    Xia, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S273 - S273
  • [44] Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations
    Cortiula, Francesco
    De Ruysscher, Dirk
    Steens, Michelle
    Wijsman, Robin
    van der Wekken, Anthonie
    Alberti, Martina
    Hendriks, Lizza E. L.
    EUROPEAN JOURNAL OF CANCER, 2023, 184 : 172 - 178
  • [45] Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial
    Thorsten O. Goetze
    Alexander Reichart
    Ulli S. Bankstahl
    Claudia Pauligk
    Maria Loose
    Thomas W. Kraus
    Moustafa Elshafei
    Wolf O. Bechstein
    Jörg Trojan
    Matthias Behrend
    Nils Homann
    Marino Venerito
    Wolfram Bohle
    Michael Varvenne
    Claus Bolling
    Dirk M. Behringer
    Karsten Kratz-Albers
    Gabriele M. Siegler
    Wael Hozaeel
    Salah-Eddin Al-Batran
    Annals of Surgical Oncology, 2024, 31 : 4073 - 4083
  • [46] SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients with Stage IIIA(N2) NSCLC - A Multicenter Single-Arm Phase II Trial
    Rothschild, S.
    Zippelius, A.
    Savic, S.
    Gonzalez, M.
    Weder, W.
    Xyrafas, A.
    Rusterholz, C.
    Pless, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S1025 - S1025
  • [47] IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab plus Chemotherapy
    Rizvi, N.
    Gandara, D.
    Solomon, B.
    Kim, A.
    Brunelli, A.
    Sun, S.
    Gitlitz, B.
    Tajima, K.
    Lin, W.
    Sandler, A.
    Peters, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S863 - S863
  • [48] Phase 3 Study of Durvalumab Combined with Oleclumab or Monalizumab in Patients with Unresectable Stage III NSCLC (PACIFIC-9)
    Griesinger, F.
    Barlesi, L.
    Goldberg, S.
    Mann, H.
    Gopinathan, A.
    Newton, M.
    Aggarwal, C.
    Heilmann, M.
    PNEUMOLOGIE, 2023, 77 : S5 - S5
  • [49] Phase 3 Study of Durvalumab Combined with Oleclumab or Monalizumab in Patients with Unresectable Stage III NSCLC (PACIFIC-9)
    Barlesi, F.
    Goldberg, S. B.
    Mann, H.
    Gopinathan, A.
    Newton, M.
    Aggarwal, C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S107 - S107
  • [50] Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study)
    Yamada, Tadaaki
    Uchino, Junji
    Chihara, Yusuke
    Shimamoto, Takayuki
    Iwasaku, Masahiro
    Tamiya, Nobuyo
    Kaneko, Yoshiko
    Kiyomi, Fumiaki
    Takayama, Koichi
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
12345